Highlights KalVista Pharmaceuticals, Inc.

Equities

KALV

US4834971032

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-05 pm EDT			5-day change	1st Jan Change
11.79 ^USD	+0.60%		+0.08%	-3.76%

Jul. 01	KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) added to Russell 3000 Growth Index	CI
Jul. 01	KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) dropped from Russell Microcap Value Index	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

KalVista Pharmaceuticals, Inc. Initiates KONFident-KID Trial for On-Demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11	Jun. 27	CI
KalVista Pharmaceuticals Submits New Drug Application to FDA for Investigational Hereditary Angioedema Treatment	Jun. 18	MT
KalVista Pharmaceuticals, Inc. Submits New Drug Application to FDA for Sebetralstat as First Oral On-Demand Treatment for Hereditary Angioedema	Jun. 18	CI
KalVista Pharmaceuticals, Inc. Presents Data At Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024	Jun. 06	CI
Kalvista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema At the European Academy of Allergy and Clinical Immunology Congress 2024	Jun. 03	CI
Sector Update: Health Care Stocks Higher Late Afternoon	May. 31	MT
Sector Update: Health Care	May. 31	MT
KalVista Prospective Treatment for Swelling Disorder Meets Objectives -- Shares Rise	May. 31	MT
Kalvista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating Its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema	May. 31	CI
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas	Mar. 18	CI
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	Mar. 11	CI
KalVista Pharmaceuticals, Inc. to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas	Mar. 08	CI
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting	Feb. 16	CI
KalVista meets main goals in late-stage trial for genetic disease	Feb. 13	RE
KalVista meets main goals in late-stage trial for skin condition treatment	Feb. 13	RE
Kalvista Pharmaceuticals, Inc. Reports Phase 3 Konfident Trial Meets All Endpoints for Sebetralstat as First Oral On-Demand Therapy for Hereditary Angioedema	Feb. 13	CI
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	Dec. 07	CI
Kalvista Pharmaceuticals Announces Phase 3 Konfident Trial Milestone Achieved	Nov. 13	CI
KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology	Nov. 02	CI
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023	23-09-07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights KalVista Pharmaceuticals, Inc.

Equities

KALV

US4834971032

Highlights

Filters